Develops Haduvio, an investigational oral therapy for chronic cough in people with idiopathic pulmonary fibrosis, other interstitial lung disease, and refractory chronic cough.
10-K for FY2025, filed Mar 17, 2026We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio…View ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
−$21.5MView ↗
Program focus
The earlier report also described Haduvio development for prurigo nodularis; the latest describes Haduvio development for chronic cough in IPF, non-IPF ILD, and refractory chronic cough.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 17, 2026We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio…View ↗
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio…View ↗
Competes with Boehringer Ingelheim, GSK, Merck &, and Nocion Therapeutics
10-K for FY2025, filed Mar 17, 2026If Haduvio is approved for the treatment of chronic cough in patients with IPF and non-IPF ILD, we expect that it may compete with product…View ↗
Loading...